The pending patent covers systemic therapeutic agents that are used in conjunction with visible light for photodynamic treatment of cancer, skin diseases, and other tissue disorders. The active compound was developed to improve the efficiency and specificity of the photodynamic process, potentially allowing treatment to be achieved quickly using minimal amounts of light.
Craig Dees, CEO of Provectus, said: “While we remain focused on clinical development of our lead therapeutic products, PV-10 for cancer and PH-10 for dermatology, this new patent solidifies an important longer-term opportunity in our development pipeline.”